MBX Biosciences (MBX) Equity Ratio (2023 - 2026)
MBX Biosciences has reported Equity Ratio over the past 4 years, most recently at 0.97 for Q1 2026.
- Quarterly results put Equity Ratio at 0.97 for Q1 2026, up 1.01% from a year ago — trailing twelve months through Mar 2026 was 0.97 (up 1.01% YoY), and the annual figure for FY2025 was 0.96, changed 0.0%.
- Equity Ratio reached 0.97 in Q1 2026 per MBX's latest filing, up from 0.96 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.97 in Q3 2025 and bottomed at 0.86 in Q4 2023.
- Median Equity Ratio over the past 4 years was 0.96 (2025), compared with a mean of 0.73.
- The largest annual shift saw Equity Ratio soared 211.36% in 2024 before it fell 0.0% in 2025.
- Over 4 years, Equity Ratio stood at 0.86 in 2023, then skyrocketed by 211.36% to 0.96 in 2024, then fell by 0.0% to 0.96 in 2025, then rose by 0.87% to 0.97 in 2026.
- Business Quant data shows Equity Ratio for MBX at 0.97 in Q1 2026, 0.96 in Q4 2025, and 0.97 in Q3 2025.